Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment news

Show

From To
Call to EU Ministers of health and CEOs of Abbvie, BMS, Gilead, Janssen and Merck/MSD regarding universal access to curative hepatitis C treatment in the EU and beyond

Together with many large NGOs EATG has signed up to a Joint Declaration urging EU Ministries of health to consider compulsory licensing as a last resort to ensure access to the HCV direct-acting antivirals.

Published
30 July 2014
From
EATG
Hepatitis C annual report: progress made, but much more to do

New figures from PHE reveal hospital admissions, liver transplants and deaths from hepatitis C (HCV) have all risen in the UK.

Published
28 July 2014
From
Public Health England
Interferon-free hepatitis C treatment works for people on methadone or buprenorphine

People with chronic hepatitis C who are using methadone or buprenorphine to manage opiate addiction can be safely and effectively treated with AbbVie's 3D all-oral direct-acting antiviral regimen

Published
25 July 2014
By
Liz Highleyman
In patients co-infected with HIV, combination antiretroviral therapy helps treat HCV

Treatment of HIV patients co-infected with the hepatitis C virus (HCV) with an anti-retroviral drug therapy not only tackles HIV, but also reduces HCV replication, according to a new study lead by a University of Cincinnati researcher. The results were published in Science Translational Medicine.

Published
25 July 2014
From
HIV / AIDS News From Medical News Today
Gilead's Sovaldi soars with sales of $3.48 billion

An excellent day for Gilead Sciences has seen the US biotech post record-breaking sales of its hepatitis C pill Sovaldi and approval in the USA for Zydelig to treat three types of blood cancer.

Published
25 July 2014
From
Pharma Times
Activists Hold Die-In to Protest High Price of Gilead’s Hepatitis C Drug

Treatment activists at the 20th International AIDS Conference held a die-in to protest the exorbitant pricing of Sovaldi (sofosbuvir), Gilead’s new hepatitis C virus (HCV) drug. As Gregg Alton, Gilead’s executive vice president of corporate and medical affairs, spoke, activists brought him a liver on a silver platter while chanting “Pills Cost Pennies, Greed Costs Lives,” “Shame, Shame, Shame,” and “Pharma Greed Kills.” Their signs said, “Wanted: Crimes Against Access,” “Hep C Criminal,” and “Gilead Kills” as the O’Jay’s “For the Love of Money” blared in the background.

Published
25 July 2014
From
Treatment Action Group
Opioid Therapy No Bar to Novel HCV Drugs

People on opioid substitution therapy for drug addiction can be safely and effectively treated for hepatitis C (HCV) with an investigational combination of medications, researchers said here.

Published
24 July 2014
From
MedPage Today
HIV, HCV and TB Pipeline Report

Drugs, diagnostics, vaccines, preventive technologies, research towards a cure, and immune-based and gene therapies in development.

Published
21 July 2014
From
Treatment Action Group & i-Base
AbbVie 3D regimen cures most genotype 1 HCV in people with HIV and HCV co-infection

An oral regimen of three direct-acting antivirals plus ribavirin taken for 12 weeks demonstrated a sustained virological response rate of 94% for people with both HIV and

Published
21 July 2014
By
Liz Highleyman
Sofosbuvir + ribavirin cures hepatitis C for more than 80% of people with HIV and HCV co-infection

An interferon-free regimen of sofosbuvir (Sovaldi) plus ribavirin for 24 weeks led to sustained hepatitis C virological response in 84 to 89% of HIV-positive people with chronic

Published
21 July 2014
By
Liz Highleyman
← First12345...41Next →

Filter by country